Biotech-focused Monterey Bio Acquisition registered to offer 10 million units at $10 each. A unit consists of one share of common stock and one warrant redeemable for a share at $11.50.
The SPAC is led by CEO Sanjeev Satyal, Ph.D., From 2018 to February 2021, Dr. Satyal served as CEO of pH Pharma Co. Inc., a clinical-stage biopharmaceutical company.
Offering manager Chardan, the representative of the underwriters, has the option to purchase up to an additional 1.5 million units to cover over-allotments, if any.
The SPAC intends to apply for a Nasdaq listing under MTRYU. Read more.
